Akston Biosciences

Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development

Antonette Ho2024-08-19T02:21:45-04:00Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, and Purdue University, today announced a strategic partnership to co-develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs. In the partnership, Akston has received an exclusive option to license the anti-cPD-L1 mAb and will serve as a Contract Development and Manufacturing Organization (CDMO) to further develop and produce the antibody at its facility in Beverly, Massachusetts.

Dechra Purchases Veterinary Insulin Programs from Akston Biosciences

Antonette Ho2024-08-15T00:08:30-04:00Dechra Limited, a global specialist veterinary pharmaceuticals and related products business, and Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announces Dechra’s purchase of all Akston’s interests in the companies’ dog and cat long-acting insulin programs. Dechra’s purchase gives it ownership of the intellectual property and rights for the development, manufacturing, and worldwide commercialization of both programs. For its interests, Akston receives an upfront cash payment, fees to support technology transfer, and near-term milestone payments...

Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors

Antonette Ho2024-06-30T13:25:56-04:00Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announced the appointment of Linda Rhodes, VMD, PhD to its Board of Directors. Dr. Rhodes brings Akston thirty years of experience in the animal health industry as a scientist, senior executive, and board member. Dr. Rhodes said, “I enjoy working with early-stage companies that have innovative solutions for animal health unmet needs. Akston combines a track record of inventing pioneering new therapies with the in-house capabilities critical...

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Antonette Ho2024-03-23T17:42:29-04:00Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Frontiers in Immunology of a study on AKS-107, an innovative antigen-specific immunotherapy based on Akston's Ambifect® Fc-fusion protein platform. The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D). Fc-fusion proteins based on this platform can be designed to interact only with parts of the immune system related to the target disease...

Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility

Antonette Ho2024-02-27T23:27:09-05:00Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Nature Vaccines of phase II study results for AKS-452, based on Akston’s Ambifect® Fc-fusion protein platform. This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine. Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures...

Akston Biosciences wins Innovation Award at Animal Health Summit

Antonette Ho2023-09-12T00:00:41-04:00Akston Biosciences Corp, a Massachusetts-based startup focused on developing long-acting protein therapeutics for pets, has received the Innovation Award at the the 2023 Animal Health Summit hosted by KC Animal Health Corridor at the Midland Theatre in Kansas City, Missouri. This is the highest distinction a company can achieve at the event. During the Emerging Companies part of the summit which consisted of a “Shark Tank-style” presentation, Akston Biosciences was among 13 animal health startups to describe their visions for...

Akston Biosciences to Focus on Strong Animal Health Pipeline

Antonette Ho2023-08-23T00:51:46-04:00Akston Biosciences Corporation announced today that it will focus on inventing, developing, and manufacturing breakthrough protein therapeutics for Companion Animal Health, utilizing its versatile Ambifect™ Fc-fusion platform and its Beverly, Massachusetts cGMP biologics manufacturing facility. Akston is spinning off its infectious disease vaccine and human Type 1 Diabetes prevention lines of business into two wholly-owned subsidiaries: Vakston, Inc. and Diamune Therapeutics, Inc. Akston’s most advanced Animal Health candidates, AKS-321d and AKS-425c, are once-a-week insulins designed to treat canine and feline...

Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA

Antonette Ho2023-03-24T16:00:03-04:00Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd. Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. AKS-452 has completed a Phase II/III clinical trial in India, with data showing robust safety profile and a 91% seroconversion rate at Day 56. Akston is now working with a...

Akston Biosciences Strengthens Board with Addition of John T. Preston

Antonette Ho2023-02-14T19:50:18-05:00Akston Biosciences Corporation, a clinical-stage biotechnology company, today announced that John T. Preston, a founder of TEM Capital, has joined its Board of Directors. A recipient of numerous awards and previous advisor to several government agencies and expert witness for Congress, Preston brings to Akston his decades of experience in technology commercialization and intellectual property licensing. Preston spent most of his career at the Massachusetts Institute of Technology (MIT), managing the interface between researchers and industry. His titles included Associate...

Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

Ziad2022-11-25T13:59:44-05:00Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 “universal” booster vaccine, AKS-452. An interim analysis of the data found that 93% of subjects previously vaccinated with Pfizer, Moderna, Johnson & Johnson (Janssen), and AstraZeneca vaccines showed an increase in neutralizing antibody titers after receiving a single dose of AKS-452. The average neutralization titers across all subjects increased 4-fold against the Wuhan strain and 5-fold against the Omicron...